OncLive SOSS

Scientific Interchange & Workshop

New Directions in CLL

May 15th 2022

Treatment Decisions in Non-Small Cell Lung Cancer

April 6th 2022

Evolving Approaches in the Treatment of AML and MDS

March 25th 2022

Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.

HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

February 25th 2022

Funding from Daiichi Sankyo; Content Developed Independently by OncLive.

Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

February 25th 2022

Funding from Daiichi Sankyo; Content Developed Independently by OncLive.

Treatment Updates and Advances in Cervical Cancer

February 7th 2022

Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low: An OncLive® Scientific Interchange and Workshop

January 21st 2022

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®

Current and Future Trends in Myelofibrosis: Cytopenias

December 13th 2021

Community Perspectives in Non-Small Cell Lung Cancer

December 8th 2021

Academic Perspectives in Non-Small Cell Lung Cancer

December 1st 2021

Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma

November 17th 2021

Updates in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

November 9th 2021

Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer

October 13th 2021

Updates in the Treatment of Waldenström Macroglobulinemia

August 13th 2021

Molecular Targets on the Horizon in Non–Small Cell Lung Cancer

July 23rd 2021

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.

Updates in the Treatment of Mantle Cell Lymphoma

July 16th 2021

Treatment Considerations in Relapsed Refractory Multiple Myeloma

July 16th 2021

Updates in the Treatment of Diffuse Large B-cell Lymphoma

July 16th 2021

Understanding the Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

July 8th 2021

Updates in ALK-Positive Non–Small Cell Lung Cancer

July 8th 2021

<
1
2
>